RCKT — Rocket Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $2.06bn
- $1.71bn
- 48
- 20
- 67
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 76.2 | 134 | 167 | 224 | 260 |
Operating Profit | -76.2 | -134 | -167 | -224 | -260 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -77.3 | -140 | -169 | -222 | -246 |
Net Income After Taxes | -77.3 | -140 | -169 | -222 | -246 |
Net Income Before Extraordinary Items | |||||
Net Income | -77.3 | -140 | -169 | -222 | -246 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -77.3 | -140 | -169 | -222 | -246 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.58 | -2.52 | -2.67 | -3.21 | -2.89 |